:max_bytes(150000):strip_icc()/VWH-MiraNorian-WeightLossDrugUpdate-4000x2700-c813fa5051604eec9c136047fb44d23a.png)
glp-1 drugs for obesity What's New in Treatment? Patients' Use GLP-1 Drugs for
Description
Lancet 2004
doi: 10.1016/j.jcjd.2019.09.003 110 HusainMBirkenfeldALDonsmarkMDunganKEliaschewitzFGFrancoDRet al
doi: 10.3389/fphys.2022.886704 25 GaberySSalinasCGPaulsenSJAhnfelt-RnneJAlanentaloTBaqueroAFet al
The efficacy was similar in monotherapy and in combination with other agents
PubMed PMID: 29617641
The potent glycemic-lowering capacity of some agents can induce a temporary worsening of DR, a phenomenon driven by rapid metabolic correction rather than direct toxicity
